Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Orthop Relat Res. 2012 Feb;470(2):428-34. doi: 10.1007/s11999-011-2126-1.

Pelvic discontinuity treated with custom triflange component: a reliable option.

Author information

  • 1Department of Orthopedic Surgery, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA. taunton.michael@mayo.edu

Abstract

BACKGROUND:

Pelvic discontinuity is an increasingly common complication of THA. Treatments of this complex situation are varied, including cup-cage constructs, acetabular allografts with plating, pelvic distraction technique, and custom triflange acetabular components. It is unclear whether any of these offer substantial advantages.

QUESTIONS/PURPOSES:

We therefore determined (1) revision and overall survival rates, (2) discontinuity healing rate, and (3) Harris hip score (HHS) after treatment of pelvic discontinuity with a custom triflange acetabular component and (4) the cost of this reconstructive operation compared to other constructs.

METHODS:

We retrospectively reviewed 57 patients with pelvic discontinuity treated with revision THA using a custom triflange acetabular component. We reviewed operative reports, radiographs, and clinical data for clinical and radiographic results. We also performed a cost comparison with utilization of other techniques. Minimum followup was 24 months (average, 65 months; range, 24-215 months).

RESULTS:

Fifty-six of 57 (98%) were free of revision for aseptic loosening at latest followup. Fifty-four (95%) were free of revision of the triflange component for any reason. Thirty-seven (65%) were free of revision for any reason. Twenty-eight (49%) were free of revision for any reason and free of any component migration and had a healed discontinuity. Forty-six (81%) had a stable triflange component with a healed pelvic discontinuity. Average HHS was 74.8. The costs of the custom triflange implants and a Trabecular Metal cup-cage construct were equivalent: $12,500 and $11,250, respectively.

CONCLUSIONS:

In this group of patients with osteolytic pelvic discontinuity, triflange implants provided predictable mid-term fixation at a cost equivalent to other treatment methods.

LEVEL OF EVIDENCE:

Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

PMID:
21997785
[PubMed - indexed for MEDLINE]
PMCID:
PMC3254733
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1A–C
Fig. 2A–D
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk